Literature DB >> 2633888

Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin.

H Wilde, P Chomchey, P Punyaratabandhu, P Phanupak, S Chutivongse.   

Abstract

Reported are the results of a retrospective study of 3156 patients who were treated at the Queen Saovabha Memorial Institute, Bangkok, with equine rabies immune globulin (ERIG). Only 51 patients (1.6%) exhibited serum-sickness-like reactions, none of which persisted for more than a week, and only 8 of these patients (15%) were treated with a short course of steroids. One patient, whose skin test was negative, had an immediate anaphylactic reaction to ERIG that responded to parenteral therapy with epinephrine and hydrocortisone sodium succinate. Serum-sickness-like reactions were more frequent among females and over 21-year-olds but were exceedingly rare (0.086%) among children under 10 years of age.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2633888      PMCID: PMC2491311     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

1.  Value of antirabies vaccine with and without serum against severe challenges.

Authors:  N VEERARAGHAVAN; T P SUBRAHMANYAN
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

2.  [Field trials with rabies vaccine on persons bitten by rabid wolves].

Authors:  M BALTAZARD; M BAHMANYAR
Journal:  Bull World Health Organ       Date:  1955       Impact factor: 9.408

3.  Laboratory data supporting the clinical trial of anti-rabies serum in persons bitten by a rabid wolf.

Authors:  K HABEL; H KOPROWSKI
Journal:  Bull World Health Organ       Date:  1955       Impact factor: 9.408

4.  Incidence of reactions to antirabies horse serum.

Authors:  T S HOSTY; F R HUNTER
Journal:  Public Health Rep       Date:  1953-08       Impact factor: 2.792

5.  Adverse effects of equine rabies immune gobulin.

Authors:  H Wilde; P Chomchey; S Prakongsri; P Puyaratabandhu; S Chutivongse
Journal:  Vaccine       Date:  1989-02       Impact factor: 3.641

6.  Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine.

Authors:  P Phanuphak; P Khawplod; S Sirivichayakul; W Siriprasomsub; S Ubol; M Thaweepathomwat
Journal:  Asian Pac J Allergy Immunol       Date:  1987-06       Impact factor: 2.310

7.  Immune sera and antiglycoprotein monoclonal antibodies inhibit in vitro cell-to-cell spread of pathogenic rabies viruses.

Authors:  D L Lodmell; L C Ewalt
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

8.  Safety of equine rabies immune globulin.

Authors:  H Wilde; P Chomchey; S Prakongsri; P Punyaratabandhu
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

9.  A clinical study of Merieux human rabies immune globulin.

Authors:  C G Helmick; C Johnstone; J Sumner; W G Winkler; S Fager
Journal:  J Biol Stand       Date:  1982-10
  9 in total
  9 in total

Review 1.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

2.  Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice.

Authors:  J B Roths; C L Sidman
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

3.  Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus.

Authors:  Pan Kyeom Kim; Sun Ju Keum; Modupe O V Osinubi; Richard Franka; Ji Young Shin; Sang Tae Park; Man Su Kim; Mi Jung Park; Soo Young Lee; William Carson; Lauren Greenberg; Pengcheng Yu; Xiaoyan Tao; Wang Lihua; Qing Tang; Guodong Liang; Madhusdana Shampur; Charles E Rupprecht; Shin Jae Chang
Journal:  PLoS One       Date:  2017-10-18       Impact factor: 3.240

4.  GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection.

Authors:  Joseph W Golden; Charles J Shoemaker; Michael E Lindquist; Xiankun Zeng; Sharon P Daye; Janice A Williams; Jun Liu; Kayla M Coffin; Scott Olschner; Olivier Flusin; Louis A Altamura; Kathleen A Kuehl; Collin J Fitzpatrick; Connie S Schmaljohn; Aura R Garrison
Journal:  Sci Adv       Date:  2019-07-10       Impact factor: 14.136

5.  Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus.

Authors:  Jia-Hai Lu; Zhong-Min Guo; Wen-Yu Han; Guo-Ling Wang; Ding-Mei Zhang; Yi-Fei Wang; Sheng-Yun Sun; Qin-He Yang; Huan-Ying Zheng; Bing L Wong; Nan-Shan Zhong
Journal:  Acta Pharmacol Sin       Date:  2005-12       Impact factor: 6.150

6.  Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.

Authors:  Thomas Müller; Bernhard Dietzschold; Hildegund Ertl; Anthony R Fooks; Conrad Freuling; Christine Fehlner-Gardiner; Jeannette Kliemt; Francois X Meslin; Richard Franka; Charles E Rupprecht; Noël Tordo; Alexander I Wanderler; Marie Paule Kieny
Journal:  PLoS Negl Trop Dis       Date:  2009-11-03

Review 7.  Subversion of the Immune Response by Rabies Virus.

Authors:  Terence P Scott; Louis H Nel
Journal:  Viruses       Date:  2016-08-19       Impact factor: 5.048

Review 8.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

9.  Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses.

Authors:  Dawn L Weir; Si'Ana A Coggins; Bang K Vu; Jessica Coertse; Lianying Yan; Ina L Smith; Eric D Laing; Wanda Markotter; Christopher C Broder; Brian C Schaefer
Journal:  Viruses       Date:  2021-03-01       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.